What infusion rate in mL per hour is required for a 93.03‑kg patient receiving dobutamine at 2.5 µg/kg/min?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Dobutamine Infusion Rate Calculation

For a 93.03 kg patient receiving dobutamine at 2.5 mcg/kg/min, you need to know the concentration of your prepared solution to calculate mL/hr.

Standard Calculation Method

The infusion rate depends entirely on your dobutamine concentration. Using the FDA-approved dosing tables 1:

For 500 mcg/mL concentration:

  • 6 mL/hr (interpolating between the 90 kg value of 5.4 mL/hr and 100 kg value of 6 mL/hr)

For 1,000 mcg/mL concentration:

  • 3 mL/hr (interpolating between the 90 kg value of 2.7 mL/hr and 100 kg value of 3 mL/hr)

For 2,000 mcg/mL concentration:

  • 1.5 mL/hr (interpolating between the 90 kg value of 1.3 mL/hr and 100 kg value of 1.5 mL/hr)

Manual Calculation Formula

If you need to calculate for any concentration:

mL/hr = (dose in mcg/kg/min × weight in kg × 60 min/hr) ÷ concentration in mcg/mL

For this patient:

  • (2.5 mcg/kg/min × 93.03 kg × 60) ÷ concentration = mL/hr
  • (13,954.5 mcg/hr) ÷ concentration = mL/hr

Clinical Context

This 2.5 mcg/kg/min dose represents the recommended starting dose for dobutamine infusion 2, 3, 1. The ESC guidelines specifically recommend starting dobutamine at 2.5 mcg/kg/min and doubling the dose every 15 minutes according to response or tolerability, with dose titration typically limited by excessive tachycardia, arrhythmias, or ischemia 2. Doses >20 mcg/kg/min are rarely needed 2.

Important Preparation Requirements:

  • Dobutamine must be diluted to at least 50 mL in an IV container using compatible diluents (D5W, NS, LR, etc.) 1
  • Solutions should be used within 24 hours 1
  • Do not mix with sodium bicarbonate or other strongly alkaline solutions 1

Monitoring During Infusion:

Monitor systemic blood pressure, urine flow, frequency of ectopic activity, heart rate, and when possible, cardiac output, central venous pressure, and/or pulmonary capillary wedge pressure 1. The optimal infusion rate varies from patient to patient, usually 2-20 mcg/kg/min 1.

References

Related Questions

What effect does a dose of 5 µg/kg/min of dobutamine have in a 2‑year‑old child weighing approximately 12 kg?
How do I calculate the infusion rate in mL/h for a dobutamine drip (e.g., for a 70‑kg adult at 5 µg/kg/min)?
What is the dose chart and drop rate per minute for a dobutamine infusion prepared by adding 250 mg to 500 mL of 5 % dextrose, for patients weighing 10 kg to 80 kg, assuming 1 mL equals 20 drops?
What are the indications, recommended dosing regimens, formulation details, and contraindications for dobutamine?
What infusion rate should be set for dobutamine (reconstituted from a 250 mg vial) in a 70‑kg adult?
How can cholecystectomy lead to chest pain?
What is the mechanism of action of Sunosi (solriamfetol)?
What are the possible causes of chest pain occurring several days after cholecystectomy and how should it be evaluated and managed?
In a 38-year-old woman with a painless, grape-sized right cervical mass present for three weeks, occasional night sweats, mild fatigue, normal appetite, no dysphagia, no prior thyroid disease, and no family history of tuberculosis or lymphoma, what is the appropriate diagnostic approach?
What could cause a transiently low thyroid‑stimulating hormone (TSH) with normal free T3 and free T4 in a 36‑year‑old woman, given that repeat testing after eight weeks shows a normal TSH and thyroid‑stimulating hormone receptor antibodies (TRAB) are negative?
What is the appropriate dose of terbinafine for an adult with dermatophyte onychomycosis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.